Interpace Diagnostics Group (NASDAQ:IDXG) Files An 8-K Other Events
Item 8.01Other Events
  As previously disclosed in a Current Report on Form 8-K filed on
  December 19, 2016, Interpace Diagnostics Group, Inc. (the
  Company) announced a registered direct public offering of
  2,000,000 shares of the Companys common stock, par value $0.01
  per share (the Common Stock), at a price of $0.53 per share and
  prefunded warrants to purchase 1,600,000 shares of Common Stock
  (the Registered Direct Offering). A copy of the legal opinion of
  Pepper Hamilton LLP relating to the legality of the issuance and
  sale of the shares of Common Stock, warrants and shares of Common
  Stock issuable upon exercise of the warrants in the Registered
  Direct Offering is filed herewith as Exhibit 5.1.
  The closing of the Registered Direct Offering is expected to take
  place on December 22, 2016, subject to customary closing
  conditions.
Forward Looking Statements
  This Current Report on Form 8-K contains forward-looking
  statements. Forward-looking statements include, but are not
  limited to, statements that express the Companys
  intentions, beliefs, expectations, strategies, predictions or
  any other statements related to the Companys
  future activities, or future events or conditions. These
  statements are based on current expectations, estimates and
  projections about the Companys business based,
  in part, on assumptions made by management. These statements are
  not guarantees of future performances and involve risks,
  uncertainties and assumptions that are difficult to predict.
  Therefore, actual outcomes and results may differ materially from
  what is expressed or forecasted in the forward-looking statements
  due to numerous factors, including those risks discussed in
  the Companys Annual Report on Form 10-K and in other
  documents that the Company files
  from time to time with the U.S. Securities and
  Exchange Commission. Any forward-looking statements
  speak only as of the date on which they are made, and
  the Company does not undertake any
  obligation to update any forward-looking statement to reflect
  events or circumstances after the date of this report, except as
  required by law.
Item 9.01.Financial Statements and Exhibits
(d)Exhibits
| Exhibit Number | Description | 
| 5.1 | Opinion of Pepper Hamilton LLP | 
| 23.1 | Consent of Pepper Hamilton LLP (included in Exhibit 5.1) | 
 About Interpace Diagnostics Group (NASDAQ:IDXG) 
 
                



